Control of Breast Cancer Using Organotin Polymers

Author： Carraher Charles E. Roner Michael R. Shahi Kimberly Moric-Johnson Alisa Miller Lindsey Barot Girish Battin Amitabh Trang Nancy T. Sookdeo Nandalall Islam Zamil

Publisher： Taylor & Francis Ltd

ISSN： 0091-4037

Source： International Journal of Polymeric Materials, Vol.64, Iss.15, 2015-11, pp. : 800-814

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The efforts described in this article are aimed at designing organotin polymers that control the growth of breast cancer and to identify structure/property relationships that assist in this goal. The growth of MCF-7 and MDA-MB-231 breast cancer cell lines is inhibited employing a wide range of organotin condensation polymers. The EC₅₀ values are primarily dependent on the nature of the Lewis base but the CI₅₀ is dependent on both the nature of the Lewis base and Lewis acid. A number of products exhibit CI₅₀ values greater than two including a number of organotin polyethers such as those derived from diethylstilbestrol, dienestrol, short-chained dibutyltin polyethers, and hydroquinone derivatives. In most of these cases the MDA-MB-231 cells exhibit greater inhibition compared to the estrogen receptor (ER) MCF-7 cells. The organotin polymers generally exhibit a superior ability to inhibit MCF-7 and MDA-MB-231 breast cell growth compared to the standard cisplatin.